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Background: Adult patients with cystic fibrosis have peripheral muscle weakness, which is related to exercise
intolerance and poor prognosis. The influence of acute exacerbations on muscle strength has been poorly studied.
This study aimed to investigate whether quadriceps force (QF), as assessed with an involuntary technique, changes
during intravenous antibiotics therapy (IVAT) for an exacerbation.
Methods: QF was measured in 20 patients using twitch stimulation of the femoral nerve at the day of
hospitalization (day 1) and at termination (day 14) of the IVAT. Physical activity was monitored during IVAT using a
SenseWear armband. Ten stable patients served as control subjects.
Results: QF did not change during exacerbation (potentiated twitch force at day 1: 140 ± 42 N, at day 14: 140 ± 47 N),
but a decrease was observed in individual patients. Changes in twitch force during exacerbation were correlated with
time spent in activities of at least moderate intensity (r = 0.61, p = 0.007).
Conclusions: QF does not systematically decrease during exacerbations of cystic fibrosis. Individual changes in QF are
well correlated with daily time spent in activities of at least moderate intensity.
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Quadriceps strengthBackground
Peripheral muscle weakness is prevalent in adult patients
with cystic fibrosis (CF) [1-3]. A 25 to 35% decrease in
quadriceps strength is observed in comparison with age-
matched healthy adults [1-3]. Quadriceps weakness is
directly related to exercise intolerance in these patients
[3]. Furthermore decreased muscle mass and exercise in-
tolerance are associated with poor prognosis [4-6]. Phys-
ical inactivity is likely to be an important underlying
factor of the observed muscle weakness [3].
CF is characterized by the occurrence of pulmonary
exacerbations which are associated with increased re-
spiratory symptoms. Frequent exacerbations negatively
influence quality of life [7], prognosis [8] and accelerate* Correspondence: thierry.troosters@med.kuleuven.be
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reproduction in any medium, provided the orlung function decline [8,9]. Exacerbations can potentially
aggravate factors underlying muscle dysfunction includ-
ing physical inactivity, systemic inflammation and ana-
bolic status [10,11]. Wieboldt et al. recently reported
that quadriceps strength at hospital admission was eight
percent lower than at convalescence one month after
hospital discharge in CF patients admitted for an acute
exacerbation [12]. No relationship was observed between
physical activity levels during hospitalization and mea-
sures of muscle strength. Muscle strength was lower at
hospital admission compared to discharge, whereas one
would expect a decrease in muscle strength during the
hospitalization due to observed inactivity during an
acute exacerbation, as has been observed in COPD [13].
In the study of Wieboldt et al., quadriceps strength was
measured by means of maximal voluntary contractions
[12]. As patients experience an increase in symptoms
during an exacerbation [14], the performance during a
maximal volitional test at the day of hospital admission
might be attenuated. Consequently, an involuntary testtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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changes in muscle strength during hospitalization for an
exacerbation. Magnetic stimulation of the femoral nerve
is a valid technique to provide an involuntary measure-
ment of quadriceps force [15]. In addition, it would be
worthwhile to objectively document physical activity
levels in terms of their intensity during and after the
acute exacerbation.
Therefore, this prospective case–control study investi-
gates whether peripheral muscle strength, assessed with
an involuntary technique, is attenuated by an acute ex-
acerbation and whether changes in muscle strength dur-
ing exacerbation can be linked with physical activity
levels. We hypothesized that quadriceps force would de-
crease in inactive patients.
Methods
Subjects
A convenience sample of 20 adult patients with CF that
were admitted to the University Hospital Gasthuisberg
in Leuven for an acute exacerbation were recruited. An
acute exacerbation was diagnosed based on the criteria
of Fuchs et al. [16]. Patients with four or more of the
following signs or symptoms were considered to have
an exacerbation and were treated with intravenous antibi-
otics: 1) increased cough; 2) increased dyspnea; 3) change
in sputum; 4) new/increased hemoptysis; 5) temperature >
38°Celsius; 6) anorexia or weight loss; 7) malaise/fatigue/
lethargy; 8) radiographic changes indicative of pulmonary
infection; 9) change in physical examination of the chest;
10) > 10% decline in pulmonary function from previous
measurement; 11) sinus pain/tenderness; 12) change in
sinus discharge. All patients received intra-venous anti-
biotic therapy (IVAT) for 14 days. A hospitalization period
of 14 days was foreseen.
Ten stable CF patients without acute exacerbation in
the preceding six months were included as stable control
patients. These patients were recruited during their an-
nual follow-up visit in the hospital and were matched
with the exacerbation group for age and gender.
Exclusion criteria were the presence of orthopedic condi-
tions interfering with the assessment of skeletal muscle
force, the occurrence of a life-threatening exacerbation, an
operation in the inguinal region in the previous two months
(contra-indication to perform magnetic stimulation) and in-
clusion in a structured exercise training program.
Written informed consent was obtained from all pa-
tients. The study protocol was approved by the local ethics
committee of University Hospital Gasthuisberg, Leuven.
Study design
Muscle strength assessment, spirometry and venous
blood sampling were performed at the beginning (day 1)
and at the end of IVAT (day 14) and one month afterIVAT (day 40 ± 3 days). Six-minute walking distance
(6MWD) was assessed at day 14 and day 40. Physical ac-
tivity levels were measured using activity monitoring
during (from day 1 till day 14) and one month after the
exacerbation (two weeks starting from day 40).
The control patients performed the same testing pro-
cedures (muscle strength, spirometry, 6MWD) at the
time of recruitment and 14 days later. Physical activity
was recorded for two weeks between the two measure-
ment sessions.
Assessment of quadriceps strength
The quadriceps force was evaluated using maximal vol-
untary contraction and transcutaneous magnetic twitch
stimulation of the right femoral nerve. Subjects were sit-
ting in a recumbent chair with hips extended at 120°,
knees flexed at 90° and arms crossed in front of the
chest. The following measures were performed in a fixed
order to obtain a comprehensive assessment of skeletal
muscle force (i.e. voluntary and involuntary muscle
strength measurement):
– Unpotentiated Quadriceps Twitch contraction
At rest, the right femoral nerve was stimulated
through a 45 mm figure-of-eight coil powered by a
double Magstim stimulator (Magstim Co Ltd.,
Whitland, Dyed, Wales, UK). The strain-gauge
signal was transformed by an analogue force
transducer (DS Europe 546QD), amplified (Model
811A amplifiers; Hewlett-Packard) and stored on a
computer. Twitch forces were measured at 30, 50,
70, 80, 90, 95 and 100% of the maximum stimulator
output and supramaximality was shown by reaching
a plateau in force output. Supramaximality was
achieved in all patients.
– Maximal Voluntary Contraction (MVC)
Subjects performed 5 isometric MVCs for three
seconds, with a resting period of at least thirty
seconds between trials For analysis, the mean of the
two highest peak force values was calculated.
– Potentiated Quadriceps Twitch contraction
The potentiated quadriceps twitch force (TWqpot)
was systematically measured three seconds after the
end of each MVC maneuver. The femoral nerve was
stimulated with a twitch at 100% of power output of
the stimulator. For analysis, the mean of the two
highest values was calculated.
Assessment of physical activity
The SenseWear Pro Armband (BodyMedia, Inc., Pittsburgh,
PA) was worn to quantify physical activity. The device
(85×54×20mm, 85 g) is placed on the upper right arm
and integrates information from a biaxial accelerometer
with signals from non-invasive sensors measuring physical
Burtin et al. Respiratory Research 2013, 14:46 Page 3 of 8
http://respiratory-research.com/content/14/1/46parameters such as changes in body temperature, near
body ambient temperature, heat flux, and galvanic skin re-
sistance. Together with individual characteristics including
gender, age, height and body mass these variables are used
to estimate energy expenditure (expressed as metabolic
equivalents of tasks, METs) utilizing proprietary equations
developed by the manufacturer. After analysis of raw data
the number of daily steps as well as daily time spent
performing activities at various intensities can be evalu-
ated. The time spent with an energy expenditure of >4.8
METS was considered as at least moderate intense phys-
ical activity. This cut-off was based on an age-based classi-
fication of physical activity intensity, as suggested by the
US Department of Health and Human Services [17].
This device provides accurate estimates of daily number
of steps and energy expenditure in patients with CF [18].
Spirometry and six-minute walking distance
Dynamic lung volumes were measured according to the
European Respiratory Society guidelines [19]. The 6MWD
tests were performed in a 50m corridor with standardized
encouragement [20].
Blood analyses
Venous blood serum samples were analyzed for hemo-
globin, blood platelets, testosterone, C-reactive protein
and white blood cells (total count and neutrophils) con-
tent. Testosterone levels were not available in the stable
patients.
Statistical analysis
All statistical analyses were performed with SAS 9.2. Data
were expressed as means ± standard deviations or medians
[interquartile range] as appropriate. Moderate intense
physical activity, testosterone levels and C-reactive protein
were not normally distributed. The level of significance
was 0.05 for all statistical tests. Repeated measures were
analyzed using repeated-measures ANOVA (with Tukey
post hoc tests), paired t-tests or Wilcoxon signed rank
tests. Comparisons between independent groups of pa-
tients were made with unpaired t-tests or Mann–Whitney
U tests where appropriate. Pearson or Spearman rank cor-
relation coefficients were used to evaluate relationships
between variables. Analysis of covariance was used to cor-
rect these relationships for baseline muscle strength.
Results
One hospitalized patient did not comply with study pro-
cedures and was excluded from analysis, leaving 19 pa-
tients (25 ± 6 years, 37% female and body mass index
(BMI) 20.9 ± 2.9) that were tested at day 1 and day 14.
IVAT was administered for the full 14 days in the hos-
pital in eleven patients, while eight patients received
IVAT at home from day 4 onwards. Seventeen patientswere tested at day 40, as two patients refused to attend
for the follow-up visit. One patient had a nickel allergy
which made it impossible to wear the activity monitor.
The ten stable CF patients (controls) had a mean age
of 29 ± 8 years, 40% were female and BMI was 20.4 ± 2.0.
One stable patient did not comply with the physical ac-
tivity measurements.
Baseline characteristics of hospitalized and stable pa-
tients are shown in Table 1, No statistical differences were
found, but chronic Pseudomonas Aeroginosa colonization
tended to be less frequent and CF-related diabetes tended
to be more frequent in the exacerbation group.
The results regarding spirometry, quadriceps strength
assessment, 6MWD, daily physical activity hematological
parameters, testosterone levels and systemic inflamma-
tion at different time points during and after the exacer-
bation and in stable patients are summarized in Table 2.
Forced expiratory volume in one second (FEV1) recov-
ered during the exacerbation (p < 0.001) to reach the
level of stable patients at day 14. At day 40, FEV1 was
decreased again to some extent (p < 0.05).
Quadriceps strength
Quadriceps strength did not change significantly during
exacerbation or follow-up (Figure 1A and B) and was
comparable with strength observed in stable patients.
At day 40, potentiated twitch force tended to be lower
in the exacerbation group compared with stable patients
(129 ± 35 vs. 158 ± 40, p = 0.06). Observations on base-
line values and changes in muscle strength were similar
between patients receiving IVAT in the hospital or partly
at home.
At day 1, potentiated twitch force and MVC were sig-
nificantly related to testosterone levels at day 1 (both r =
0.82, p < 0.0001), but not with inflammatory markers
(white blood cells, neutrophils, C-reactive protein).
The absolute value of the change in muscle force be-
tween day 1 and day 14 in patients with exacerbations
(Twqpot 7 [5-13]%; MVC 6 [0–15]%) was comparable
with the random variability observed with the two
strength measurements in the control group (Twqpot 6
[2-10]%; MVC 6 [3-8]%). Figure 2 shows the distribution
of the change in twitch force (Figure 2A) and MVC
(Figure 2B). In the exacerbation group a numerically
higher proportion of patients had a larger decrease in
muscle strength over the 14 days.
Daily physical activity
The amount of daily steps and daily time spent in at
least moderate intense activities was lower during the
exacerbation but increased to the level of stable patients
during follow-up (p < 0.05, Figure 3A and B). Physical
activity levels were not significantly different between
patients receiving IVAT in the hospital (4283 [3276–







(n = 19) (n = 10)
Age (yrs) 25 ± 6 29 ± 8 0.14
Gender (male/female) 13/6 6/4 0.70
BMI (kg/m2) 20.9 ± 2.9 20.4 ± 2.0 0.63
Chronic PA colonization (n) 14 (74%) 10 (100%) 0.07
CF-related diabetes mellitus (n) 11 (58%) 2 (20%) 0.051
Pancreas insufficiency (n) 16 (84%) 9 (90%) 0.67
Genotype ΔF508/ΔF508 (n) 12 (63%) 5 (50%) 0.49
# Exacerbations in 12 months
prior to inclusion
1 [0–2] 0 [0–1] 0.09
Data are presented as mean ± standard deviation or median [interquartile range].
BMI = body mass index, PA = Pseudomonas Aeruginosa, CF = cystic fibrosis.
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above 4.8 METs) and patients partly receiving IVAT at
home (3517 [2411–7468] steps/day and 4 [2-18] min
spent in activities above 4.8 METs). No difference in ac-
tivity levels was observed between males and females.Table 2 Spirometry, quadriceps strength, functional exercise





FEV1 (L) 2.1 ± 0.9**
,#
FEV1 (%pred) 55 ± 19**
,##
FVC (L) 3.5 ± 1.0**
Quadriceps strength and functional exercise capacity
Twqpot (N) 140 ± 42
MVC (N) 378 ± 128
6MWD (m) /
Physical activity
Daily steps (n) 4654 ± 2929#,§
Time > 4.8 METs (min) 6 [2-17] #
Hematological parameters, testosterone and systemic inflammation
Hemoglobin (g/dL) 13.9 ± 1.5
Blood platelets (x109/L) 314 ± 109*
Testosterone (in men) (ng/dL) 249 [148–281]
WBC count (x109/L) 12.6 ± 4.3**,#,§
Neutrophil count (x109/L) 8.6 ± 3.0**,§
CRP (mg/L) 13 [8–48]**,§
Data are presented as mean ± standard deviation or median [interquartile range].
Data in the stable group are data from the first assessment, except for physical acti
period.FEV1 = forced expiratory volume in one second; %pred = percentage of the p
twitch force; MVC =maximal voluntary contraction force of the quadriceps, 6MWD =
cells, CRP = C-reactive protein. *p < 0.05 vs. day 14 **, p < 0.001 vs. day 14, # p < 0.05Systemic inflammation and testosterone
White blood cell, neutrophil and CRP concentrations were
elevated at day 1 and normalized by day 14. At day 40,
these parameters tended to increase again and white blood
cell and neutrophil count were significantly higher com-
pared with stable patients (p < 0.05). Serum testosterone
levels in men with CF remained unchanged during the
exacerbation.
Changes in quadriceps strength during IVAT, physical
activity and systemic inflammation
Change in TWqpot was significantly related with moderate
intense physical activity during exacerbation (r = 0.61, p =
0.007, Figure 4A), but not with the daily number of steps (r
= −0.15, p = 0.55, Figure 4B). Seventy percent of patients
who spent less than 10 minutes per day in moderate intense
physical activity showed a decrease in twitch force, com-
pared to 25% of patients with more daily moderate intense
activity (p = 0.057). Change in MVC was not correlated
with measures of physical activity during exacerbation (r =
0.29, p = 0.24 for moderate intense physical activity; r =




(n = 17) (n = 10)
Day 14 Day 40
2.7 ± 1.1# 2.4 ± 1.0 2.8 ± 1.0
69 ± 25# 61 ± 23 72 ± 22
4.0 ± 1.2 3.7 ± 1.2 4.1 ± 0.8
140 ± 47 129 ± 35 158 ± 40
369 ± 119 353 ± 109 456 ± 157
694 ± 89§ 698 ± 84§ 786 ± 111
7174 ± 4423 7414 ± 2810
14 [4–40] 11 [6–35]
13.7 ± 1.6 13.8 ± 1.4 14.8 ± 1.2
287 ± 104 339 ± 87 250 ± 63
354 [251–442] 256 [209–363] /
8.6 ± 3.1 9.9 ± 2.3§ 7.4 ± 2.2
5.2 ± 2.4 7.1 ± 2.4§ 4.7 ± 1.8
3 [0–5] 9 [7-18] § 2 [0–7]
vity measurements, which are the mean values over a 14-day assessment
redicted value; FVC = forced vital capacity; Twqpot = potentiated quadriceps
six-minute walking distance, MET =metabolic equivalent, WBC = white blood
vs. day 40, ## p < 0.001 vs. day 40, §p < 0.05 vs. stable.
Figure 1 Individual quadriceps strength, represented as potentiated twitch force (1A) and maximum voluntary contraction (1B), during
exacerbation and one month after exacerbation (day 40).
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was not related with physical activity or blood parameters
after correction for baseline muscle strength.
No relationships were observed between hematological
variables, testosterone levels and parameters of systemic
inflammation on the one hand and changes in muscle
strength on the other hand.
Discussion
This study shows that quadriceps force does not system-
atically decrease during exacerbations of CF. Interest-
ingly, the daily time spent in at least moderate intense
activities is closely linked with individual changes in
quadriceps twitch force during the same period.
Muscle strength
Quadriceps weakness is known to be present in more
than 50% of stable patients [3], but the contribution of
exacerbations to the development of such weakness is
unknown. We observed no systematic detrimental im-
pact of an acute exacerbation on muscle force. A wide-
spread variability of quadriceps force change is observed
among CF patients. This observation is not in line with
a recent study where quadriceps strength, as measuredFigure 2 Cumulative histogram of changes in potentiated twitch forc
between day 1 and day 14 in patients during exacerbation (black barby volitional maximal maneuvers, was significantly in-
creased in adult CF patients during hospital admission
for an acute exacerbation (14). By definition, patients
with CFexperience an increase in symptoms at the onset
of an exacerbation [21]. A recent study shows that 93%
of patients reported increased dyspnea and 84% reported
feelings of malaise during acute exacerbations [14].
These symptoms potentially have an influence on the re-
sult of a maximal volitional test of muscle strength, espe-
cially at hospital admission. This could possibly explain
the observed increase in muscle strength during exacerba-
tion in the study of Wieboldt et al. [12]. Interestingly, our
results did not confirm the findings of Wieboldt et al., as
no systematic change in MVC was observed. Anyhow, the
use of magnetic stimulation of the femoral nerve to assess
quadriceps strength has the potential to overcome the
possible influence of increased symptoms on muscle
strength measurements. This technique is an involuntary,
well-tolerated and valid technique to assess quadriceps
strength in healthy subjects and patients with chronic ob-
structive pulmonary disease [15,22,23].
The variability of the change in muscle force in CF pa-
tients during an exacerbation was similar to the random
between-measurement variability found in stable CFe (TWqpot, 2A) and maximum voluntary contraction (MVC, 2B)
s) and stable patients (white bars).
Figure 3 Individual physical activity levels (time spent in activities with an energy demand > 4.8 MEts indicating moderate intense
physical 3A; daily number of steps, 3B) during and one month after an exacerbation and in stable patients. *p<0.05 vs. day 40,
# p<0.05 vs stable patients.
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tients appeared to have a pronounced decrease in
muscle force. Similar variability of quadriceps force as-
sessments (both maximal voluntary maneuvers and mag-
netic twitch force) has been reported [23,24].
Physical activity
During IVAT, both the amount (daily steps) and the in-
tensity (time spent in activities of at least moderate in-
tensity) of daily physical activity are reduced compared
to stable controls. The daily number of steps was 36%
lower in patients with an exacerbation compared with
stable controls, whereas time spent in activities of at
least moderate intensity was even more reduced.
Hospitalization itself might be a reason underlying this
marked inactivity, as patients spent their days indoor.
Interestingly, however, patients that continued IVAT at
home from day 4 onwards were not more active than
patients that completed IVAT in the hospital. The IVAT
and the increased respiratory symptoms are possible rea-
sons for the observed inactivity. One month after theFigure 4 Relationship between daily physical activity (time spent in a
intense physical activity, 4A; daily number of steps, 4B) and change iexacerbation, physical activity increased to the level of
stable patients, but especially time spent in at least mod-
erate intense activities was still clearly below levels ob-
served in healthy age-matched adults in literature
(median 14 min/day vs. 35 min/day) [3].
Whereas individual changes in twitch force during
antibiotic therapy were strongly correlated with daily
time spent in activities of at least moderate intensity, no
relationship was found with the daily number of steps.
This is in line with previous observations of our group
that time spent in moderate intense physical activity but
not daily number of steps is related with exercise toler-
ance and quadriceps force in patients with stable CF (3).
Moreover, the recent study of Wieboldt et al. demon-
strated that a reduction in quadriceps strength during an
acute CF exacerbation did not correlate with daily steps,
however, the relationship with moderate intense physical
activity was not investigated [12]. As showed in our
study, patients with very low levels of moderate intense
physical activity (less than ten minutes per day) seem
more vulnerable to a decrease in muscle force.ctivities with an energy demand > 4.8 METs indicating moderate
n potentiated twitch force (TWqpot) during an exacerbation.
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Although white blood cell, neutrophil and C-reactive
protein serum concentrations are clearly increased at
the onset of the exacerbation, no relationship is ob-
served between blood parameters of inflammation and
muscle force. Unfortunately we did not take muscle bi-
opsies to investigate local muscle inflammation. Serum
testosterone levels were strongly related to quadriceps
strength, which is not in line with the findings of Barry
et al. [25]. This might be explained by the observation
that over 75% of our male patients had low testoster-
one levels (<300 ng/dL) whereas Barry et al. reported
normal levels. However, testosterone levels did not
change over time and were not related to changes in
quadriceps force.
Future research
It is tempting to speculate that moderate intense exer-
cise training could be an interesting intervention to pre-
vent deterioration of the muscle in those patients that
do not voluntarily engage in these activities. This might
be particularly important in patients with frequent exac-
erbations. The impact of repeated respiratory exacerba-
tions on muscle function has not yet been investigated
in patients with CF. If, due to respiratory symptoms,
physical activity is difficult to achieve, resistance training
or neuromuscular electrical stimulation could perhaps
be considered, as both are associated with a limited ven-
tilatory load. These approaches have been shown to im-
prove muscle strength in patients with a pulmonary
infection [26] and stable patients with several pulmonary
impairment [27,28].
Conclusions
Quadriceps strength does not systematically decrease
during exacerbations of cystic fibrosis. Individual
changes in quadriceps strength are well correlated with
the daily time spent in activities of at least moderate
intensity.
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